Our Take
Buyers are rationing risk, not capital: deal value climbs while deal count falls, signaling consolidation among fewer, larger players willing to absorb policy uncertainty.
Why it matters
Healthcare finance officers and M&A teams need to understand the shift from volume to selectivity. Smaller deals are being starved of attention while buyers bet bigger on fewer, higher-conviction targets.
Do this week
Healthcare CFO: audit your deal pipeline against buyer selectivity patterns (larger check sizes, fewer targets per buyer) before Q2 board forecasts so you can reset valuation and timeline expectations.
M&A activity bifurcates in healthcare
Healthcare M&A deal volume is down in 2026, but deal values have climbed compared to the first half of 2025, according to analysis from PwC. The divergence reflects a shift in buyer behavior: consolidators are growing more selective, concentrating capital on fewer, larger transactions while stepping back from smaller deals.
Policy and reimbursement uncertainty are the primary brakes. Buyers face heightened visibility challenges on regulatory headwinds and payment model shifts, forcing them to screen targets more rigorously. The result is fewer total deals, but those that close tend to be bigger bets.
Selectivity concentrates power among larger players
This pattern has a structural consequence: deal flow is consolidating upward. Mid-market and smaller health services firms now face a narrower buyer pool. The consolidators doing deals are those with balance sheets and operational bandwidth to absorb policy risk, which favors well-capitalized PE firms, hospital systems, and large health tech platforms over smaller strategic buyers.
For sellers and their advisors, the message is uncomfortable. Fewer buyers in market means less competitive tension, which typically pressures valuation multiples. Sellers of smaller or mid-sized health services assets will need stronger operational proof points (EBITDA stability, customer stickiness, regulatory compliance certainty) to stand out in a buyer's tighter screening process.
Pin your deal thesis to buyer selectivity
If you are preparing a health services asset for sale, assume your buyer pool has contracted and become more conservative on policy exposure. Build your pitch around operational resilience to reimbursement change, not growth optimism. Buyers in 2026 are asking "can this business survive headwinds?" before they ask "how much can it grow?"
For those on the buy side, the message is different: if you are sizing up a health services acquisition, recognize that you have outsized leverage in negotiation. Fewer competitors chasing deals means seller desperation is rising. Use that to demand tighter earnouts, longer reps and warranties, and deeper operational diligence before committing.